Drug Approval | June 14, 2022
FDA accepts application for Merck’s Keytruda as adjuvant therapy for Stage IB-IIIA lung cancer
Acceptance based on results from the phase 3 KEYNOTE-091 trial
Acceptance based on results from the phase 3 KEYNOTE-091 trial
Next-generation booster vaccine candidate demonstrates potential to protect against COVID-19 variants of concern, including Omicron BA.1 and BA.2, with a favorable safety and tolerability profile
India’s first oncology laboratory for comprehensive Cancer Diagnostic services
SPLASH also houses the tools’ calibration for epMotion, Eppendorf automated liquid handling workstations.
Plans to establish six state of the art TaCa Centre for Surgery in next 2 years in these states
TAK-003 is currently undergoing regulatory review for potential licensure in both the European Union
New Director supports NASDAQ rule on diversity
During the research term, Olema will contribute funding to Aurigene to facilitate ongoing discovery efforts.
The Accelerator will develop products and solutions that will support Sanofi’s mission to transform the practice of medicine with the use of digital, data and artificial intelligence (AI).
Dupixent is the first and only biologic medicine approved to treat moderate-to-severe atopic dermatitis from infancy to adulthood
Subscribe To Our Newsletter & Stay Updated
